The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx)-Global Market Insights and Sales Trends 2025

Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx)-Global Market Insights and Sales Trends 2025

Publishing Date : Mar, 2025

License Type :
 

Report Code : 1828126

No of Pages : 88

Synopsis
The global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) market size is expected to reach US$ 24730 million by 2029, growing at a CAGR of 14.7% from 2023 to 2029. The market is mainly driven by the significant applications of Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) in various end use industries. The expanding demands from the Oncology, Neurological Disorders, Cardiovascular Disease and Immunological Disorders, are propelling Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) market. PCR, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the In-situ Hybridization segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx), with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) covered in this report include Qiagen NV, GE Healthcare, Agilent Technologies, F Hoffman La Roche, Foundation Medicine, Thermo Fisher Scientific Inc., Leica Biosystems Nussloch GmBH and Pfizer, etc.
The global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Qiagen NV
GE Healthcare
Agilent Technologies
F Hoffman La Roche
Foundation Medicine
Thermo Fisher Scientific Inc.
Leica Biosystems Nussloch GmBH
Pfizer
Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) market, Segment by Type:
PCR
In-situ Hybridization
Immunohistochemistry
Sequencing
Others
Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) market, by Application
Oncology
Neurological Disorders
Cardiovascular Disease
Immunological Disorders
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index
1 Market Overview of Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx)
1.1 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Overview
1.1.1 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Product Scope
1.1.2 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Status and Outlook
1.2 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Region (2018-2029)
1.4 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Historic Market Size by Region (2018-2023)
1.5 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size (2018-2029)
1.6.1 North America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size (2018-2029)
1.6.2 Europe Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size (2018-2029)
1.6.3 Asia-Pacific Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size (2018-2029)
1.6.4 Latin America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size (2018-2029)
1.6.5 Middle East & Africa Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size (2018-2029)
2 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market by Type
2.1 Introduction
2.1.1 PCR
2.1.2 In-situ Hybridization
2.1.3 Immunohistochemistry
2.1.4 Sequencing
2.1.5 Others
2.2 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Historic Market Size by Type (2018-2023)
2.2.2 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue Breakdown by Type (2018-2029)
3 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Overview by Application
3.1 Introduction
3.1.1 Oncology
3.1.2 Neurological Disorders
3.1.3 Cardiovascular Disease
3.1.4 Immunological Disorders
3.1.5 Others
3.2 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Historic Market Size by Application (2018-2023)
3.2.2 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue Breakdown by Application (2018-2029)
4 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Competition Analysis by Players
4.1 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) as of 2022)
4.3 Date of Key Players Enter into Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market
4.4 Global Top Players Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Headquarters and Area Served
4.5 Key Players Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Product Solution and Service
4.6 Competitive Status
4.6.1 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Qiagen NV
5.1.1 Qiagen NV Profile
5.1.2 Qiagen NV Main Business
5.1.3 Qiagen NV Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Products, Services and Solutions
5.1.4 Qiagen NV Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue (US$ Million) & (2018-2023)
5.1.5 Qiagen NV Recent Developments
5.2 GE Healthcare
5.2.1 GE Healthcare Profile
5.2.2 GE Healthcare Main Business
5.2.3 GE Healthcare Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Products, Services and Solutions
5.2.4 GE Healthcare Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue (US$ Million) & (2018-2023)
5.2.5 GE Healthcare Recent Developments
5.3 Agilent Technologies
5.3.1 Agilent Technologies Profile
5.3.2 Agilent Technologies Main Business
5.3.3 Agilent Technologies Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Products, Services and Solutions
5.3.4 Agilent Technologies Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue (US$ Million) & (2018-2023)
5.3.5 F Hoffman La Roche Recent Developments
5.4 F Hoffman La Roche
5.4.1 F Hoffman La Roche Profile
5.4.2 F Hoffman La Roche Main Business
5.4.3 F Hoffman La Roche Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Products, Services and Solutions
5.4.4 F Hoffman La Roche Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue (US$ Million) & (2018-2023)
5.4.5 F Hoffman La Roche Recent Developments
5.5 Foundation Medicine
5.5.1 Foundation Medicine Profile
5.5.2 Foundation Medicine Main Business
5.5.3 Foundation Medicine Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Products, Services and Solutions
5.5.4 Foundation Medicine Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue (US$ Million) & (2018-2023)
5.5.5 Foundation Medicine Recent Developments
5.6 Thermo Fisher Scientific Inc.
5.6.1 Thermo Fisher Scientific Inc. Profile
5.6.2 Thermo Fisher Scientific Inc. Main Business
5.6.3 Thermo Fisher Scientific Inc. Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Products, Services and Solutions
5.6.4 Thermo Fisher Scientific Inc. Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue (US$ Million) & (2018-2023)
5.6.5 Thermo Fisher Scientific Inc. Recent Developments
5.7 Leica Biosystems Nussloch GmBH
5.7.1 Leica Biosystems Nussloch GmBH Profile
5.7.2 Leica Biosystems Nussloch GmBH Main Business
5.7.3 Leica Biosystems Nussloch GmBH Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Products, Services and Solutions
5.7.4 Leica Biosystems Nussloch GmBH Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue (US$ Million) & (2018-2023)
5.7.5 Leica Biosystems Nussloch GmBH Recent Developments
5.8 Pfizer
5.8.1 Pfizer Profile
5.8.2 Pfizer Main Business
5.8.3 Pfizer Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Products, Services and Solutions
5.8.4 Pfizer Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue (US$ Million) & (2018-2023)
5.8.5 Pfizer Recent Developments
6 North America
6.1 North America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Dynamics
11.1 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Industry Trends
11.2 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Drivers
11.3 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Challenges
11.4 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List

Published By : QY Research

Why ‘The Market Reports’